Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression

Authors:
  • EGEllen Gelpi
    Ellen Gelpi
  • DPDaniela Prayer
    Daniela Prayer
  • KDKarin Dieckmann
    Karin Dieckmann
  • CMChristian Matula
    Christian Matula
  • MHMarco Hassler
    Marco Hassler
  • JHJohannes A Hainfellner
    Johannes A Hainfellner
  • CMChristine Marosi
    Christine Marosi

Abstract
We report on a male patient with progressive and metastatic clivus chordoma treated over a period of 9 years by a multidisciplinary approach. Within the first 4 years, the patient underwent surgery four times. Thereafter, he received radiotherapy and subsequent chemotherapy. Stabilization of disease was achieved repeatedly for variable periods under local radiotherapy, systemic chemotherapy, immunomodulatory and anti-angiogenic therapy with isotretinoin and interferon-alpha, followed by thalidomide. Due to the occurrence of brain and lung metastases 8 years after initial diagnosis, liposomal doxorubicin was added to thalidomide. At the last follow-up control the patient had stable disease, with no progression of the intracranial tumor and regression of pulmonary metastases. He is in a good physical, psychological and neurological condition with a Karnofsky score of 80. Our observations show that multimodal therapy including a systemic palliative approach is associated with long quiescent intervals in recurrent chordoma and with regression of its metastases. Use of substances with high efficacy on tumor tissue and low toxicity, allowing long-term administration, seems promising in similar situations.

This publication has 19 references indexed in Scilit: